Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Tolazoline: α2-Adrenergic Receptor Antagonist & ATP-Sensi...

    2026-04-01

    Tolazoline: α2-Adrenergic Receptor Antagonist and ATP-Sensitive Potassium Channel Blocker

    Executive Summary: Tolazoline (CAS 59-98-3) is an imidazoline-based pharmacological agent that antagonizes α2-adrenergic receptors and inhibits ATP-sensitive K+ channels in pancreatic β cells, thereby enhancing insulin secretion and modulating airway smooth muscle tone (APExBIO, Tolazoline A8991). At 10 μM, Tolazoline inhibits 86Rb efflux from mouse islets by 8.1%, increasing to 13.7% at 100 μM, and achieves ~20% ATP-sensitive K+ channel blockade at 500 μM under in vitro conditions. The compound exhibits a -logKi of ~6.80 for rat brain α2-adrenergic receptors and reverses clonidine-induced insulin inhibition above 31.8 μM. It is soluble in DMSO (≥29.7 mg/mL), ethanol (≥31 mg/mL), and water (≥6.14 mg/mL, ultrasonic). APExBIO's Tolazoline serves as a benchmark tool for islet and airway research, supporting reproducibility in both in vitro and in vivo animal models (TolazolineAPIS, 2023).

    Biological Rationale

    Tolazoline is an imidazoline compound that selectively antagonizes α2-adrenergic receptors. These receptors regulate neurotransmitter release and smooth muscle tone in multiple tissues, including airways and islets. By blocking ATP-sensitive potassium channels in pancreatic β cells, Tolazoline promotes insulin release in response to elevated glucose. In airways, it inhibits cholinergic neurotransmitter release, contributing to smooth muscle relaxation. The dual mechanism positions Tolazoline as a precise tool for dissecting neuroendocrine and respiratory physiology in vitro and in animal models (TolazolineAPIS).

    Mechanism of Action of Tolazoline

    Tolazoline competitively antagonizes α2-adrenergic receptors with a -logKi of approximately 6.80 in rat cerebral cortex membrane assays. This antagonism leads to increased neurotransmitter release and enhanced insulin secretion. Additionally, Tolazoline blocks ATP-sensitive K+ channels in pancreatic β cells, attenuating K+ efflux (measured by 86Rb release) and depolarizing the membrane. This triggers voltage-dependent Ca2+ influx and insulin exocytosis. In the airways, antagonism of α2-adrenergic and K+ channels modulates smooth muscle tone, relevant for bronchodilation models (APExBIO). Tolazoline’s efficacy is concentration-dependent, with observable effects from 10 nM to 500 μM in vitro, and animal model applications at 0.12 mg/kg IV in horses for blocking xylazine-induced bronchodilation (TolazolineAPIS, 2022).

    Evidence & Benchmarks

    • At 10 μM, Tolazoline inhibits 86Rb efflux from isolated mouse pancreatic islets by 8.1% under standard glucose conditions (APExBIO, product page).
    • At 100 μM, inhibition increases to 13.7%, indicating dose-dependent K+ channel blockade (APExBIO, product page).
    • ATP-sensitive K+ channel blockade reaches ~20% at 500 μM in in vitro islet assays (APExBIO, product page).
    • Reversal of clonidine-induced insulin secretion inhibition requires at least 31.8 μM Tolazoline (APExBIO, product page).
    • -logKi for α2-adrenergic receptors in rat cerebral cortex is ~6.80, confirming competitive antagonism (APExBIO, product page).
    • In vivo, 0.12 mg/kg IV Tolazoline blocks xylazine-mediated bronchodilation in horses (TolazolineAPIS, 2022).
    • Solubility is documented at ≥29.7 mg/mL in DMSO, ≥31 mg/mL in ethanol, and ≥6.14 mg/mL in water (ultrasonication) (APExBIO, product page).
    • For broader context on dopaminergic and adrenergic receptor targeting, see the evidence backbone: Benitez et al., 2014.

    Applications, Limits & Misconceptions

    Tolazoline is primarily used in pharmacological research to dissect α2-adrenergic receptor signaling and ATP-sensitive potassium channel pathways in both neuroendocrine and airway models. It is validated for:

    • Quantitative studies of insulin secretion modulation in isolated rodent islets.
    • Airway smooth muscle tone regulation in in vitro and in vivo animal models.
    • Pharmacological dissection of α2-adrenergic receptor pathways in neuroscience research.
    • Benchmarking with other imidazoline derivatives for specificity and potency.

    This article updates and extends the mechanistic detail compared to 'Tolazoline: Expanding Frontiers in α2-Adrenergic Research' by providing precise in vitro and in vivo quantitative data and solubility parameters for experimental reproducibility.

    Common Pitfalls or Misconceptions

    • Not a universal α2 antagonist: Tolazoline requires higher concentrations than some other imidazoline derivatives for full α2-adrenergic antagonism.
    • ATP-sensitive K+ channel blocking is partial: Even at 500 μM, Tolazoline achieves only ~20% blockade in islet assays.
    • Limited long-term solution stability: Tolazoline solutions are not recommended for extended storage; fresh preparation is advised.
    • Species and tissue variability: Pharmacodynamics may differ among animal models; always validate concentration and response in context.
    • Not approved for human therapeutic use: Tolazoline is intended for research applications only.

    Workflow Integration & Parameters

    Tolazoline (SKU A8991) from APExBIO is supplied as a high-purity powder. Typical in vitro use ranges from 10 nM (receptor binding) to 500 μM (channel blockade). It dissolves readily in DMSO (≥29.7 mg/mL), ethanol (≥31 mg/mL), and water (≥6.14 mg/mL with ultrasonic assistance). For islet and airway studies, solutions should be freshly prepared and stored at -20°C if short-term storage is unavoidable. APExBIO’s validated supply chain supports assay reproducibility (TolazolineAPIS, 2023). For practical integration tips and troubleshooting, this article clarifies and updates 'Tolazoline (SKU A8991): Enhancing Reproducibility in Islet Function Assays' with new quantitative benchmarks and workflow advice.

    Conclusion & Outlook

    Tolazoline remains a benchmark pharmacological tool for α2-adrenergic receptor and ATP-sensitive K+ channel research. Its dual mechanism enables precise dissection of insulin secretion and airway smooth muscle tone in vitro and in vivo. Documented solubility and validated concentration-response profiles from APExBIO support reproducibility across neuroendocrine and respiratory research models. Future research may further define structure-activity relationships and optimize Tolazoline derivatives for translational and mechanistic studies. For advanced mechanistic analysis, see 'Tolazoline at the Translational Frontier: Mechanistic Insight into Islet and Airway Pharmacology', which this article extends by adding detailed solubility data and workflow parameters.